Corcept Therapeutics Incorporated (CORT)

Cash ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash and cash equivalents	US$ in thousands	127,665	137,289	128,588	149,750	135,551	111,800	172,377	465,057	436,619	50,243	381,976	61,862	335,812	94,688	95,430	52,381	476,892	30,560	58,523	349,005
Short-term investments	US$ in thousands	255,669	243,047	344,568	261,011	232,670	243,425	190,885	165,115	365,343	346,019	334,740	283,665	145,918	266,643	274,552	320,578	364,506	398,233	346,835	222,838
Total current liabilities	US$ in thousands	140,773	126,216	100,750	97,202	104,505	121,873	93,059	25,216	81,588	53,068	54,038	57,244	6,908	44,757	45,402	40,601	10,554	43,048	42,243	36,005
Cash ratio		2.72	3.01	4.70	4.23	3.52	2.91	3.90	24.99	9.83	7.47	13.26	6.04	69.74	8.07	8.15	9.19	79.72	9.96	9.60	15.88

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($127,665K + $255,669K) ÷ $140,773K
= 2.72

The cash ratio of Corcept Therapeutics Incorporated has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The ratio measures the company's ability to cover its short-term debt obligations with its available cash and cash equivalents.

The cash ratio ranged from a high of 79.72% on December 31, 2020, indicating a substantial cash reserve relative to short-term obligations, to a low of 2.72% on December 31, 2024, suggesting a significant decrease in available cash compared to short-term liabilities.

Throughout the period, the company maintained a generally healthy cash position relative to its short-term obligations, with the ratio mostly above the industry average. However, there were several quarters with lower ratios, indicating a potential strain on liquidity.

It is important for investors and stakeholders to closely monitor the cash ratio trend of Corcept Therapeutics to assess the company's ability to meet its short-term debt obligations and manage liquidity effectively.